CLDF Title
Home | Contact Us | Bookmark
About CLDF Centers of Educational Expertise  
Webcasts Slide Library Abstract Library Conference Highlights
Reuters Health Information (2012-04-26): Vertex posts profit but Incivek (telaprevir) sales decline


Vertex posts profit but Incivek (telaprevir) sales decline

Last Updated: 2012-04-26 18:30:12 -0400 (Reuters Health)

(Reuters) - Vertex Pharmaceuticals Inc on Thursday reported lower-than-expected first-quarter profit and revenue as sales of its new hepatitis C drug Incivek (telaprevir) declined faster than anticipated.

Incivek had sales of $356.9 million, down from $456.8 million in the previous quarter and below Wall Street estimates of about $390 million.

That gives the drug, which has helped to double cure rates for the serious liver disease over older treatments, cumulative sales of about $1.3 billion since its approval last May, making it the fastest drug to eclipse $1 billion in sales in pharmaceutical history.

The swift decline would suggest that early pent-up demand has been satisfied or that some patients are beginning to wait for new all-oral treatment regimens with fewer side effects that are being developed by several companies, including Vertex.

Vertex maintained its full-year forecast for Incivek sales of $1.5 billion to $1.7 billion.

Slide Library
Abstract Library
Slide Library
Abstract Library
Slide Library
Abstract Library
Slide Library
Abstract Library
CLDF Follow Us
About CLDF
Mission Statement
Board of Trustees
Board of Advisors
CLDF Supporters
Other Resources
Liver News Library
Journal Abstracts
Hep C Link to Care
Centers of
Educational Expertise
Regional Map
  The Chronic Liver Disease Foundation is a non-profit organization with content developed specifically for healthcare professionals.
© Copyright 2012-2015 Chronic Liver Disease Foundation. All rights reserved. This site is maintained as an educational resource for US healthcare providers only.
Use of this Web site is governed by the Chronic Liver Disease Foundation terms of use and privacy statement.